Study of liver inflammation from immunotherapy drugs
Treatments studied
Part of Digestive system clinical trials.
This study follows people who develop liver inflammation (hepatitis) after starting immunotherapy for cancer. It helps doctors understand how often this happens and how to manage it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You are being treated for cancer with an immunotherapy drug (checkpoint inhibitor), alone or with other treatments
- You have received at least one dose of an immunotherapy drug
- You developed liver inflammation (hepatitis) after starting immunotherapy, shown by certain blood test results
- Your liver inflammation is considered moderate to severe (grade 3 or 4)
- You do not have another cause of liver inflammation, like a virus or alcohol
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for certain markers in the blood that can help diagnose liver inflammation caused by immunotherapy. It aims to better understand this side effect and how to treat it.
This study looks at how well immune-checkpoint therapy (a PD-1 or PD-L1 immunotherapy) works for advanced liver cancer, using “liquid biopsy” blood testing to guide or monitor care. It may help your team better track your cancer and response without needing repeated tissue biopsies.
This study looks at why some people develop liver inflammation after checkpoint inhibitor cancer treatment, called checkpoint inhibitor–induced liver injury (ChILI). It compares people with ChILI to similar cancer patients who are starting the same type of immunotherapy, to better understand and track these liver injury events.
This trial studies a way to treat inflammation of the liver (hepatitis) caused by immune cancer medicines (anti-PD-1/PD-L1, sometimes with anti-CTLA-4) without relying on high-dose steroids. It may help reduce steroid side effects while keeping liver inflammation under control.
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Hear when a new Liver Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.